Effect of atorvastatin on dyslipidemia and carotid intima-media thickness in children with refractory nephrotic syndrome: a randomized controlled trial.

Background: Dyslipidemia is an important cardiovascular risk factor in steroid-resistant nephrotic syndrome (SRNS). Efficacy of statins for treatment of hyperlipidemia in children with SRNS is unclear.Methods: This prospective, randomized, double-blind, placebo-controlled, parallel-group clinical tr...

Descripción completa

Detalles Bibliográficos
Publicado en:Pediatric Nephrology Vol. 33; no. 12; pp. 2299 - 2310
Autores principales: Hari, Pankaj, Khandelwal, Priyanka, Satpathy, Amit, Hari, Smriti, Thergaonkar, Ranjeet, Lakshmy, R, Sinha, Aditi, Bagga, Arvind
Formato: research tables/charts randomized controlled trial Journal Article
Publicado: Springer Nature Dec2018
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=132697976&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 132697976
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        0931041X
        EF1
      jtl: Pediatric Nephrology
      issn: 0931041X
      maglogo: N
    pubinfo:
      dt: Dec2018
      vid: 33
      iid: 12
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        132697976
        132697976
        132697976
        10.1007/s00467-018-4036-x
        132697976
      ppf: 2299
      ppct: 11
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Effect of atorvastatin on dyslipidemia and carotid intima-media thickness in children with refractory nephrotic syndrome: a randomized controlled trial.
      aug:
        au:
          Hari, Pankaj
          Khandelwal, Priyanka
          Satpathy, Amit
          Hari, Smriti
          Thergaonkar, Ranjeet
          Lakshmy, R
          Sinha, Aditi
          Bagga, Arvind
        affil: Division of Nephrology, Department of Pediatrics, All India Institute of Medical Sciences, Ansari Nagar, 110029, New Delhi, India
      sug:
        subj:
          Hyperlipidemia In Infancy and Childhood
          Carotid Intima-Media Thickness In Infancy and Childhood
          Hyperlipidemia Drug Therapy
          Atorvastatin Drug Effects
          Nephrotic Syndrome
          Human
          Randomized Controlled Trials
          Random Assignment
          Child, Preschool
          Child
          Adolescence
          Prospective Studies
          Lipoproteins, HDL Cholesterol Blood
          Atorvastatin Therapeutic Use
          Placebos
          Treatment Outcomes
          Descriptive Statistics
          Apolipoproteins
          Child, Preschool: 2-5 years
          Child: 6-12 years
          Adolescent: 13-18 years
      ab: Background: Dyslipidemia is an important cardiovascular risk factor in steroid-resistant nephrotic syndrome (SRNS). Efficacy of statins for treatment of hyperlipidemia in children with SRNS is unclear.Methods: This prospective, randomized, double-blind, placebo-controlled, parallel-group clinical trial enrolled 30 patients with SRNS, aged 5-18 years, with serum low-density lipoprotein cholesterol (LDL-C) levels between 130 and 300 mg/dl, to receive a fixed dose of atorvastatin (n = 15, 10 mg/d) or placebo (n = 15) by block randomization in a 1:1 ratio. Primary outcome was change in serum LDL-C at 12 months. Change in levels of other lipid fractions, carotid intima-media thickness (cIMT), flow-mediated dilation (FMD) of the brachial artery, and adverse events were also evaluated.Results: At the end of 12 months, atorvastatin was not superior to placebo in reducing plasma LDL-C levels, median percentage reduction 15.8% and 9.5% respectively, in atorvastatin and placebo arms (n = 14 in each; P = 0.40). Apolipoprotein B levels significantly declined with atorvastatin in modified intention-to-treat analysis (P = 0.01) but not in the per-protocol analysis. There was no significant effect on other lipid fractions, cIMT and FMD. Adverse events were similar between groups. Change in serum albumin was negatively associated with change in serum LDL-C, very low-density lipoprotein cholesterol, total cholesterol, triglyceride, and apolipoprotein B (P < 0.001), irrespective of receiving atorvastatin, age, gender, body mass index, and serum creatinine.Conclusions: Atorvastatin, administered at a fixed daily dose of 10 mg, was not beneficial in lowering lipid levels in children with SRNS; rise in serum albumin was associated with improvement in dyslipidemia.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        randomized controlled trial
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N